Zetta Genomics

Zetta Genomics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Zetta Genomics is a private, revenue-generating bioinformatics platform company focused on solving the data management and analysis bottleneck in genomic medicine. Its core product, XetaBase, is a genomic-native variant store built on open-source technology (OpenCB) that aggregates and indexes hundreds of thousands of genomes to enable rapid, scalable querying and re-interpretation. The company targets healthcare systems, life sciences firms, and research institutions, positioning itself as an essential infrastructure player to enable precision medicine at population scale. Its deep academic roots and proven deployment in large-scale projects provide a strong foundation for growth in the expanding genomic data market.

Genetics & Genomics

Technology Platform

XetaBase: A cloud-native, genomic variant store and analysis platform built on the open-source OpenCB stack. It aggregates and indexes hundreds of thousands of genomes for rapid querying, visualization, and re-interpretation in research and clinical settings.

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The massive growth of population genomics initiatives and the integration of genomics into clinical diagnostics create a vast need for scalable data management platforms.
The rise of AI/ML in healthcare also drives demand for well-structured, queryable genomic datasets as a foundational resource.

Risk Factors

Faces intense competition from large cloud providers and established bioinformatics firms.
Long sales cycles and high barriers to adoption in regulated healthcare systems pose significant commercial challenges.
Must continuously innovate to handle increasing data scale and complexity.

Competitive Landscape

Competes in the genomic data platform market against large cloud hyperscalers (AWS, Google, Microsoft), specialized bioinformatics SaaS companies (e.g., DNAnexus), and legacy informatics tools. Differentiation is based on its genomic-native architecture, proven scalability from the 100,000 Genomes Project, and dual research/clinical functionality.